InMode (NASDAQ:INMD) updated its fourth quarter 2020
Pre-Market earnings guidance on Tuesday. The company provided EPS guidance of 0.91-0.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.62. The company issued revenue guidance of $74.5-75 million, compared to the consensus revenue estimate of $63.72 million.InMode also updated its FY 2020
Pre-Market guidance to 2.08-2.10 EPS.
Several analysts have recently commented on the stock. Robert W. Baird raised their price objective on shares of InMode from $43.00 to $55.00 and gave the company an outperform rating in a research report on Tuesday, October 13th. They noted that the move was a valuation call. ValuEngine downgraded shares of InMode from a buy rating to a hold rating in a research report on Monday, November 23rd. UBS Group lifted their price target on shares of InMode from $43.00 to $47.00 and gave the company a buy rating in a report on Wednesday, October 14th. BidaskClub downgraded shares of InMode from a strong-buy rating to a buy rating in a report on Thursday, December 31st. Finally, Canaccord Genuity lifted their price target on shares of InMode from $42.00 to $51.00 and gave the company a buy rating in a report on Wednesday, October 21st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $48.00.
Shares of NASDAQ:INMD opened at $55.22 on Thursday. InMode has a 52 week low of $13.14 and a 52 week high of $55.37. The stock has a market capitalization of $1.77 billion, a P/E ratio of 39.73 and a beta of 1.96. The firm has a fifty day simple moving average of $46.14 and a two-hundred day simple moving average of $38.02.
InMode Company Profile
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
See Also: What does an outperform rating mean?
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.